Discovery of Novel Pyridazine-Containing Nicotinamide Derivatives as Potent FTO Inhibitors for Acute Myeloid Leukemia
- 4 October 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 24420-24443
Abstract
FTO has been recognized as a promising therapeutic target for acute myeloid leukemia (AML). However, the development of FTO inhibitors with anti-leukemia effects was still limited. Here, based on reasonable design and SAR, a total of 67 compounds were synthesized, among which compound E6 exhibited the strongest activity (FTO IC50 = 5.3 μM, KD = 3.25 μM). MST, CETSA, and DARTS detection confirmed its binding to FTO target. In addition, compound E6 exhibited good activity against MOLM-13 cells and induced it apoptosis. Mechanistic studies shown that compound E6 increased global m6A levels in AML cells, upregulated the FTO downstream targets ASB2 and RARA, and suppressed c-Myc expression. Importantly, compound E6 exhibited acceptable CYP safety and pharmacokinetic properties, significantly inhibited the growth of MOLM-13 xenograft tumors. These results provided novel chemical scaffold for discovery of FTO inhibitor against leukemia.Keywords
Funding Information
- Anhui Provincial Department of Education (2024AH010013)
- National Natural Science Foundation of China (22377001)
- Anhui Medical University (2023xktdyxa2)
This publication has 39 references indexed in Scilit:
- Development of 3-arylaminothiophenic-2-carboxylic acid derivatives as new FTO inhibitors showing potent antileukemia activitiesEuropean Journal of Medicinal Chemistry, 2025
- Small molecules that regulate the N6-methyladenosine RNA modification as potential anti-cancer agentsEuropean Journal of Medicinal Chemistry, 2024
- Chemical Inhibitors Targeting the Oncogenic m6A Modifying ProteinsAccounts of Chemical Research, 2023
- FTO in cancer: functions, molecular mechanisms, and therapeutic implicationsTrends in Cancer, 2022
- A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activitiesActa Pharmaceutica Sinica B, 2021
- Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillanceCell Metabolism, 2021
- R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axisMolecular Cell, 2021
- Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionCancer Cell, 2020
- Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid LeukemiaCancer Cell, 2019
- FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA DemethylaseCancer Cell, 2017